HIV-1 latency in monocytes/macrophages
- PMID: 24759213
- PMCID: PMC4014723
- DOI: 10.3390/v6041837
HIV-1 latency in monocytes/macrophages
Abstract
Human immunodeficiency virus type 1 (HIV-1) targets CD4+ T cells and cells of the monocyte/macrophage lineage. HIV pathogenesis is characterized by the depletion of T lymphocytes and by the presence of a population of cells in which latency has been established called the HIV-1 reservoir. Highly active antiretroviral therapy (HAART) has significantly improved the life of HIV-1 infected patients. However, complete eradication of HIV-1 from infected individuals is not possible without targeting latent sources of infection. HIV-1 establishes latent infection in resting CD4+ T cells and findings indicate that latency can also be established in the cells of monocyte/macrophage lineage. Monocyte/macrophage lineage includes among others, monocytes, macrophages and brain resident macrophages. These cells are relatively more resistant to apoptosis induced by HIV-1, thus are important stable hideouts of the virus. Much effort has been made in the direction of eliminating HIV-1 resting CD4+ T-cell reservoirs. However, it is impossible to achieve a cure for HIV-1 without considering these neglected latent reservoirs, the cells of monocyte/macrophage lineage. In this review we will describe our current understanding of the mechanism of latency in monocyte/macrophage lineage and how such cells can be specifically eliminated from the infected host.
Figures


Similar articles
-
HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes.J Leukoc Biol. 2010 Apr;87(4):575-88. doi: 10.1189/jlb.0409264. Epub 2009 Oct 2. J Leukoc Biol. 2010. PMID: 19801499 Review.
-
Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage.Retrovirology. 2010 Apr 9;7:32. doi: 10.1186/1742-4690-7-32. Retrovirology. 2010. PMID: 20380694 Free PMC article. Review.
-
Eradication of HIV-1 from the macrophage reservoir: an uncertain goal?Viruses. 2015 Mar 31;7(4):1578-98. doi: 10.3390/v7041578. Viruses. 2015. PMID: 25835530 Free PMC article. Review.
-
Cellular reservoirs of HIV-1 and their role in viral persistence.Curr HIV Res. 2008 Sep;6(5):388-400. doi: 10.2174/157016208785861195. Curr HIV Res. 2008. PMID: 18855649 Free PMC article. Review.
-
Monocyte to macrophage differentiation and changes in cellular redox homeostasis promote cell type-specific HIV latency reactivation.Proc Natl Acad Sci U S A. 2024 May 7;121(19):e2313823121. doi: 10.1073/pnas.2313823121. Epub 2024 Apr 29. Proc Natl Acad Sci U S A. 2024. PMID: 38683980 Free PMC article.
Cited by
-
Characteristics and mechanisms of latency-reversing agents in the activation of the human immunodeficiency virus 1 reservoir.Arch Virol. 2023 Nov 29;168(12):301. doi: 10.1007/s00705-023-05931-2. Arch Virol. 2023. PMID: 38019293 Review.
-
Human immunodeficiency virus (HIV)-1 integration sites in viral latency.Curr HIV/AIDS Rep. 2015 Mar;12(1):88-96. doi: 10.1007/s11904-014-0241-9. Curr HIV/AIDS Rep. 2015. PMID: 25573791 Free PMC article. Review.
-
Phosphatidylcholine Liposomes Down-Modulate CD4 Expression Reducing HIV Entry in Human Type-1 Macrophages.Front Immunol. 2022 May 19;13:830788. doi: 10.3389/fimmu.2022.830788. eCollection 2022. Front Immunol. 2022. PMID: 35663973 Free PMC article.
-
Mannose-decorated hybrid nanoparticles for enhanced macrophage targeting.Biochem Biophys Rep. 2019 Jan 25;17:197-207. doi: 10.1016/j.bbrep.2019.01.007. eCollection 2019 Mar. Biochem Biophys Rep. 2019. PMID: 30723809 Free PMC article.
-
Mechanisms underlying of antiretroviral drugs in different cellular reservoirs with a focus on macrophages.Virulence. 2020 Dec;11(1):400-413. doi: 10.1080/21505594.2020.1760443. Virulence. 2020. PMID: 32375558 Free PMC article. Review.
References
-
- Hammer S.M., Squires K.E., Hughes M.D., Grimes J.M., Demeter L.M., Currier J.S., Eron J.J., Jr., Feinberg J.E., Balfour H.H., Jr., Deyton L.R., et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS clinical trials group 320 study team. N. Engl. J. Med. 1997;337:725–733. doi: 10.1056/NEJM199709113371101. - DOI - PubMed
-
- Davey R.T., Jr., Bhat N., Yoder C., Chun T.W., Metcalf J.A., Dewar R., Natarajan V., Lempicki R.A., Adelsberger J.W., Miller K.D., et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA. 1999;96:15109–15114. doi: 10.1073/pnas.96.26.15109. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials